GuanaRep
Repurposing guanabenz for Vanishing White Matter, taking an academic discovery through clinical development, pharmaceutical development and a registration pathway designed around patient access.
to an accessible treatment.
A blood-pressure drug.
A potential VWM treatment.
Academic research at Amsterdam UMC identified guanabenz, an existing antihypertensive medicine, as a potential treatment for Vanishing White Matter.
The programme has progressed through preclinical research and a Phase I/II study. The development challenge now is to convert that clinical evidence into the pharmaceutical and regulatory package required for registration.
science
structure
progression
access
GuanaRep
Vanishing White Matter
Connecting the trial to a route towards approval.
Clinical evidence in hand.
Registration is the next route.
The goal is not simply approval. It is access for every VWM patient.
GuanaRep is organised as a public-private partnership, bringing academia, patient organisations, funders, investors and pharmaceutical specialists together around a socially responsible route to market.